Solbinsiran not checked

Eli Lilly · LY3561774

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
1 active
3 in total
Targets
—
None known yet

What this is

How it works
A short strand of RNA that switches off one gene, so the body makes less of one protein.-siran: small interfering RNA WHO name stem
Tested for
Severe Hypertriglyceridemia
Main trialPhase 2
“The purpose of this study is to evaluate the safety and efficacy of solbinsiran in lowering triglycerides and other lipid measures compared to placebo in participants with severe hypertriglyceridemia. Participants will receive two subcutaneous injections.”In the company’s words, NCT07269210 on ClinicalTrials.gov
Other names
LY3561774

Other drugs for Severe Hypertriglyceridemia

All 15 drugs for Severe Hypertriglyceridemia

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 2Recruiting Mar 2027 A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia
Phase 2Completed 4 Mar 2024 A Study of LY3561774 in Participants With Mixed Dyslipidemia
Phase 1Completed 17 May 2022 A Study of LY3561774 in Participants With Dyslipidemia
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Solbinsiran

Following is part of Solo: you see every change to Solbinsiran the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in